Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Support MFO
Donate through PayPal
ClearBridge $2 Stock Buy Reaches $480 On Alzheimer’s Drug
FYI: (This is a follow-up on thread started by Scott:) Biogen Idec Inc. has been a winning stock for many money managers -- none more so than Richard Freeman.
Freeman, who has run the $15.2 billion ClearBridge Aggressive Growth Fund for more than 30 years and now co-manages the fund with Evan Bauman, in 1991 first bought the company’s shares for the equivalent of less than $2. The stock surged as much as 11 percent to more than $480 on Friday on news of promising results for an experimental drug to treat Alzheimer’s, bringing gains this year to almost 40 percent
